2023-05-12 22:10:11
“I came out to raise IQVIA’s awareness and publicize its role as a partner at a time when Korea’s biopharmaceutical industry is growing.”
IQVIA Korea, a company specializing in clinical development and data, participated in BIOKOREA 2023 for the first time this year and is actively communicating with the domestic pharmaceutical bio industry.
As more and more companies are contemplating entering the global market due to the rapid growth of biopharmaceuticals, IQVIA announced programs within IQVIA that can support them and set out to establish contact points.
Bio Korea 2023 opened on the 10th and is being held for three days with various programs under the theme of ‘The Era of Hyper-Connection, Leap to New Growth Innovative Technology’. It celebrated its 18th anniversary this year, and it consisted of business partnering, exhibition, conference, and investment fair with the participation of 730 companies from 51 countries.
An IQVIA official who came out to support the field said, “IQVIA is a company that provides services to pharmaceutical companies, so I participated to show what kind of service it has.” It’s a movement,” he said.
Looking at the booth, it contained information on various services such as ▲R&D solution ▲Pharma Tech solution ▲Real World&Analytics solution ▲Market insights.
Although IQVIA is supported through various stages from the drug stage to clinical trials and post-marketing tracking, it was regrettable that the awareness of each stage of service was limited, so the main purpose is to comprehensively inform all of them in one place.
In particular, as many new drug development companies consider strategies to shorten the development period as important as investment costs, they emphasized support for this.
Among them, the publicity method that caught the eye was the kiosk consultation, which provided a service that visitors to the booth might make inquiries in according to the field they wanted consultation, such as drug clinical development strategy and licensing strategy.
In addition, by making it possible to see and experience the AI technology implemented by Pharma Tech solutions, etc., many visitors came to the booth to increase understanding.
Ultimately, a strategy to achieve scalability in the domestic pharmaceutical bio industry from a long-term perspective through these contact points.
An official from IQVIA said, “When we receive inquiries, there is a prejudice that IQVIA only works for large companies.” We will continue our efforts to have scalability.”
Meanwhile, on the 11th, IQVIA held an analysis session on the global status of distributed clinical trials to find out the global trend of distributed clinical trials and discuss ways to vitalize DCT in Korea.
1683946616
#Emphasis #IQVIA #Bio #Koreas #surprise #booth #biopharmaceutical #partner
